Calm vs Incyte
Side-by-side comparison of AI visibility scores, market position, and capabilities
Calm is a leading mental wellness app offering sleep, meditation, and relaxation content with enterprise health benefits programs serving over 100 million downloads.
About
Calm is a digital mental health company founded in 2012 by Michael Acton Smith and Alex Tew that has grown into one of the most downloaded and highest-grossing health apps globally. The platform offers guided meditations, sleep stories narrated by celebrities, breathing exercises, and relaxing music designed to reduce stress, improve sleep quality, and support overall mental wellness. Calm has exceeded 100 million downloads and reached a $2B valuation with backing from TPG, making it one of the most valuable standalone consumer wellness applications. The company has expanded into enterprise with Calm Business, providing employee mental health and wellbeing benefits to thousands of organizations. Calm has invested heavily in content production, partnering with prominent voices including LeBron James, Matthew McConaughey, and Harry Styles for exclusive audio content. The company also offers Calm Kids with age-appropriate mindfulness content for children. While positioned primarily as a consumer wellness tool rather than a clinical platform, Calm's scale and brand recognition have made it a leading solution for companies seeking accessible, low-friction mental wellness benefits for large employee populations.
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
About
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.